S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:PASG

Passage Bio Price Target, Predictions & Analyst Ratings

$2.02
+0.19 (+10.38%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.86
$2.05
50-Day Range
$1.63
$3.46
52-Week Range
$1.57
$16.14
Volume
539,923 shs
Average Volume
603,092 shs
Market Capitalization
$109.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.85

Passage Bio (NASDAQ:PASG) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Buy
Based on 7 Analyst Ratings

Analyst Price Target Consensus

$17.00
741.58% Upside

High PT$34.00
Average PT$17.00
Low PT$6.00
TypeCurrent
5/21/21 to 5/21/22
1 Month Ago
4/21/21 to 4/21/22
3 Months Ago
2/20/21 to 2/20/22
1 Year Ago
5/21/20 to 5/21/21
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
5 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$17.00$20.00$24.00$27.20
Price Target Upside741.58% Upside298.01% Upside131.92% Upside20.40% Upside
Get Passage Bio Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Passage Bio (NASDAQ:PASG) vs. Its Competitors

TypePassage BioMedical CompaniesS&P 500
Consensus Rating Score
2.71
2.72
2.52
Consensus RatingBuyBuyBuy
Price Target Upside741.58% Upside460.16% Upside29.33% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
38
69.09%
Underperform Votes
17
30.91%
Avg. Outperform Votes
171
67.06%
Avg. Underperform Votes
84
32.94%
Avg. Outperform Votes
839
69.28%
Avg. Underperform Votes
372
30.72%

Passage Bio (NASDAQ:PASG) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/17/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Price TargetNA$11.00+497.82%
5/17/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Price TargetBuy$15.00 ➝ $10.00+491.71%
3/11/2022Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Price Target$43.00 ➝ $34.00+1,054.50%
3/8/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral
3/4/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Price TargetOutperform$29.00 ➝ $24.00+686.88%
3/3/2022Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chico
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
1/19/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$29.00 ➝ $6.00+11.11%
2/4/2021Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$25.00+21.36%
12/11/2020Smith Barney Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$2.21-91.98%
3/24/2020Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
(Data available from 5/21/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Passage Bio (NASDAQ:PASG) Analyst Ratings Frequently Asked Questions

What is Passage Bio's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Passage Bio stock is Buy based on the current 2 hold ratings and 5 buy ratings for PASG. The average twelve-month price target for Passage Bio is $17.00 with a high price target of $34.00 and a low price target of $6.00. Learn more on PASG's analyst rating history.

Do Wall Street analysts like Passage Bio more than its competitors?

Analysts like Passage Bio stock less than the stock of other Medical companies. The consensus rating score for Passage Bio is 2.71 while the average consensus rating score for medical companies is 2.72. Learn more on how PASG compares to other companies.

Do MarketBeat users like Passage Bio more than its competitors?

MarketBeat users like Passage Bio stock more than the stock of other Medical companies. 69.09% of MarketBeat users gave Passage Bio an outperform vote while medical companies recieve an average of 67.06% outperform votes by MarketBeat users.

Is Passage Bio being downgraded by Wall Street analysts?

Over the previous 90 days, Passage Bio's stock had 1 downgrade by analysts.

Does Passage Bio's stock price have much upside?

According to analysts, Passage Bio's stock has a predicted upside of 341.75% based on their 12-month price targets.

What analysts cover Passage Bio?

Passage Bio has been rated by BTIG Research, Chardan Capital, Citigroup, JPMorgan Chase & Co., Raymond James, and Wedbush in the past 90 days.

This page was last updated on 5/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.